Quarterly report [Sections 13 or 15(d)]

Fair Value of Financial Instruments - Summary of contingent consideration related to acquisition (Details)

v3.26.1
Fair Value of Financial Instruments - Summary of contingent consideration related to acquisition (Details) - USD ($)
3 Months Ended
Feb. 21, 2025
Mar. 31, 2026
Mar. 31, 2025
Business Combination [Line Items]      
Balance, beginning   $ 3,061,501  
Change in fair value contingent consideration $ (4,435,443) (373,354) $ (1,164,864)
Balance, ending   0  
CorHepta [Member]      
Business Combination [Line Items]      
Balance, beginning   3,061,501 0
Additions   0 4,435,443
Issuance of common stock   (2,688,147) 0
Change in fair value contingent consideration   (373,354) (1,164,864)
Balance, ending   $ 0 $ 3,270,579